Trials / Completed
CompletedNCT04154072
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 255 (actual)
- Sponsor
- Neuraly, Inc. · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NLY01 | exenatide and polyethylene glycol (PEG) |
| DRUG | Vehicle | Saline (Sodium Chloride) |
Timeline
- Start date
- 2020-02-27
- Primary completion
- 2023-02-14
- Completion
- 2023-02-14
- First posted
- 2019-11-06
- Last updated
- 2024-09-19
Locations
61 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04154072. Inclusion in this directory is not an endorsement.